1. No category

LAURENCE H. BELKOFF, D.O., M.Sc., F.A.C.O.S.
Curriculum Vitae
OFFICE ADDRESSES:
1 Presidential Blvd, Suites 100 & 115
Bala Cynwyd, PA 19004
(610) 667-3020
Fax: (610) 667-1817
Email – [email protected]
231 N. Broad Street
2nd Floor
Philadelphia, PA 19107
Phone (215) 762-3200
2705 DeKalb Pike, Suite 302
Norristown, PA 19401
Phone (610) 277- 0313
EMPLOYMENT HISTORY:
PROFILE:
Urologic Surgery, PC – 1987 to 12/31/06
Urologic Consultants of Southeastern Pennsylvania – 1/1/07 to Present
Chairman and Professor, Department of Specialty Surgeries
and Division of Urology, Philadelphia College of Osteopathic Medicine
Past President, American College of Osteopathic Surgeons
Partner, Urologic Consultants of Southeastern Pennsylvania
Principal Investigator, Urologic Consultants of Southeastern Pennsylvania
PLACE OF BIRTH:
Elizabeth, New Jersey
LICENSERS:
Pennsylvania State Board of Examiners (Active)
New Jersey State Board of Examiners (Active)
EDUCATION:
COLLEGE:
Emory University
Atlanta, Georgia
Degree: B.A. (1974-1978)
MEDICAL SCHOOL:
Kansas City University of Medicine and Biosciences
College of Osteopathic Medicine
Kansas City, Missouri
Degree: D.O. (1978-1982)
INTERNSHIP:
Botsford General Hospital
Farmington Hills, Michigan
2
(1982-1983)
RESIDENCY:
Detroit Osteopathic Hospital
Highland Park, Michigan
Resident, General Surgery (1983 -1984)
John Finley, DO., Chairman
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
Resident, Urologic Surgery (1984 -1987)
Leonard H. Finkelstein, DO, Chairman
Chief Resident - 1986 -1987
Metropolitan Hospital, Central Division
Philadelphia, PA
Nephrology
William Nickey, DO, Chairman
Children’s Hospital of Philadelphia
Philadelphia, PA
Pediatric Urology
John Duckett, MD., Chairman
Albert Einstein Medical Center
Philadelphia, PA
Urologic Surgery
Robert Klause, MD, Chairman
Memorial Sloan-Kettering Cancer Center
New York, NY
Urologic Oncology
William Fair, MD
MASTER OF SCIENCE:
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
Urologic Surgery - June 1987
BOARD CERTIFICATION:
American Osteopathic Board of Surgery
Urologic Surgery – June 21, 1992
FELLOWSHIP:
Fellow of the American College of Osteopathic Surgeons
San Diego, California - September 1996
HONORARY DEGREE:
Doctor of Laws
Philadelphia College of Osteopathic Medicine,
Philadelphia, PA June 2, 2002
POST GRADUATE
CERTIFICATION:
Extracorporeal Shock Wave Lithotripsy
Hospital of the University of Pennsylvania
January 1988
3
(Training program - AUA Lithotripsy Training Committee)
Laparoscopy Endourology (Electrocautery and Laser)
Philadelphia College of Osteopathic Medicine – April 18, 1991
Candela Laser Training Program
Albert Einstein Medical Center - March 27, 1993
KTP/532 and Nd/YAG Laser Training Program
Albert Einstein Medical Center – June 5, 1993
Injectable “Collagen” Therapy for Urinary Incontinence – November 6, 1995
Prostate Brachy Therapy Training
Lee Memorial Health System – January 28 & 29, 2000
Course in Pelvic Floor Reconstruction
Thomas Jefferson Hospital – May 16 & 17, 2003
Targeted Cryoablation of the Prostate - Regional Training Workshop
USMD Hospital, Arlington, Texas – February 21 – 22, 2006
High Dose Rate Brachy Therapy for Prostate Cancer
Seattle Prostate Institute – February 27-28, 2006
Green Light PVP Laser Training
Hahnemann University Hospital – April 19, 2006
CURRENT HOSPITAL
AFFILIATIONS:
Mercy Suburban Hospital
Norristown, PA
1996 – Continuing
Albert Einstein Medical Center
Philadelphia, PA
2000 - Continuing
Hahnemann University Hospital
Philadelphia, PA
2004 – Continuing
Jeanes Hospital
Philadelphia, PA
2009 – Continuing
St. Joseph’s Hospital
Philadelphia, PA
2009 - Continuing
4
FACULTY STAFF POSITIONS:
Chairman, Department of Surgical Specialties, Philadelphia College of Osteopathic Medicine, July 2004 to present
Chairman, Division of Urology, Philadelphia College of Osteopathic Medicine, July 2006 to present
Professor of Urology, Philadelphia College of Osteopathic Medicine, July 2000 to present
Assistant Clinical Professor, Department of Surgery, Division of Urology, Drexel University College of Medicine, January
2000 to present
Associate Director Urology Residency Program – Philadelphia College of Osteopathic Medicine, 2005 to present
Associate Professor of Urology, Philadelphia College of Osteopathic Medicine, 1991 - 2000
Assistant Professor of Urology, Philadelphia College of Osteopathic Medicine, 1989 - 1991
Instructor of Urology, Philadelphia College of Osteopathic Medicine, 1989 - 1991
Member, Intern Committee, 1991 - 2000
FACULTY STAFF POSITIONS: Continued:
Member, Medical Records Committee, Hahnemann University Hospital, 2005 - 2010
Member, Intern Selection Committee, 1991 - 2002
Clinical Chairman, Division of Urology, PCOM, City Avenue Hospital, 1994 - 2000
Divisional Urologic Residency Program Director, City Avenue Hospital & Parkview Hospital, 1994 - 2000
Member, Bio-Medical Ethics Committee, Philadelphia College of Osteopathic Medicine, 1990 - 1998
Member, Tumor Board Committee, Philadelphia College of Osteopathic Medicine, 1989 - 2000
Member, Medical Audit/Record Committee, Philadelphia College of Osteopathic Medicine, 1991 - 2000
Member, Medical Executive Board - Graduate City Avenue & Parkview Hospitals, 1993
Member, Infection Control Committee, Philadelphia College of Osteopathic Medicine, 1989 - 1998
Member, Transfusion Committee, Philadelphia College of Osteopathic Medicine, 1989 - 1991
Member, Pharmacy and Therapeutics Committee, 1993 - 2000
Member, Medical Executive Board - Graduate City Avenue Hospital, 1994, 1995
Chairman, Institutional Review Board (IRB) Allegheny City Avenue Hospital, 1994 - 1997
Vice Chairman Medical Staff, Allegheny City Avenue Hospital, 1995-1997
President, Medical Staff, City Avenue Hospital, 1997 – 1999
Medical Director, City Avenue Hospital, 1999 – 2000
Clinical Service Chief for Osteopathic Medicine – Medical College of Pennsylvania Hospital, 2000 - 2004
5
Director of Osteopathic Affairs – Medical College of Pennsylvania Hospital, 2000 - 2004
Member, Peer Review Committee, MCP Hospital, 2000 - 2004
Member, Surgery Advisory Committee, MCP Hospital, 2000 - 2004
Member, Performance Improvement Committee, MCP Hospital, 2000 - 2004
Member, Hospital Services Operations Committee, MCP Hospital, 2000 - 2004
Member, Strategic Planning Committee, MCP / PCOM / Hahnemann University / Parkview Hospitals, 2000 - 2004
Member, Medical Executive Board, MCP Hospital, 2000 - 2004
Vice-Chairman, By-Laws Committee, MCP Hospital, 2003 – 2004
PROFESSIONAL ASSOCIATIONS:
Member, American Osteopathic Association, 1992 to present
Associate Member, American Urologic Association, 2009
Member, Pennsylvania Osteopathic Medical Association, 1987 to present
Member, Pennsylvania Medical Society, 1991 to present
Member, Pennsylvania Urologic Society, 1991 to present
Member, American College of Osteopathic Surgeons, 1989 to present
Member, Sigma Sigma Phi Fraternity (Osteopathic Scholarship & Leadership Fraternity), 1982 to present
Faculty Advisor, Sigma Sigma Phi Fraternity, Philadelphia College of Osteopathic Medicine
Member, Omicron Delta Kappa Fraternity (Scholarship & Leadership Fraternity, Emory University)
ALUMNI ASSOCIATIONS:
Member, Newark Academy, Livingston, NJ - 1974 to present
Member, Emory University, Atlanta, GA - 1978 to present
Member, University of Health Sciences/College of Osteopathic Medicine - 1982 to present
HONORS AND AWARDS:
ACOS President’s Special Recognition Award, October 1999, Seattle Washington
The University Service Award (UHS/COM June,1982)
Who’s Who in the American Colleges and Universities 1980-1981
6
Meade Johnson Fellowship Grant, 1985
Second Place, Resident Essay Contest, A.C.O.S., Urologic Discipline - October, 1985
First Place, Resident Essay Contest, A.C.O.S., Urologic Discipline - October, 1986
The Resident Achievement Award, American College of Osteopathic Surgeons - October, 1986
Second Place, Resident Essay Contest, POMA – May, 1987
NATIONAL AND STATE COMMITTEES:
Alternative Delegate, AOA House of Delegates, 1993, 1994
Delegate, House of Delegates, Pennsylvania Osteopathic Medical Association, 1993, 1994, 1995
Alternate, House of Delegates, Pennsylvania Osteopathic Medical Association, 1996 - 2001
Member, Committee on Surgery - Urologic (POMA) 1992 - 1994
Chairman, Committee on Surgery - Urologic (POMA) 1994 - 1998
Guest Editorial Referee, J.A.O.A. 1991
Member, Relative Update Committee, AOA, 1991
Member, Pennsylvania Medical Society, 1991 - 1998
Member, Committee on Organization Membership and Physician Placement (POMA), 1995
Member, ACOS Awards Committee, 1993 - 1996
Chairman, Awards Committee, American College of Osteopathic Surgeons, 1995 - 2005
Chairman, Committee Surgery - Urologic (POMA) 1994 - 1996
Program Chairman, American College of Osteopathic Surgeons, Division of Urology, Atlanta GA, 9/20/97 - 9/23/97
Secretary, Urologic Discipline, American College of Osteopathic Surgeons, 9/97 to present
Chairman-Elect, Urologic Discipline, American College of Osteopathic Surgeons, 1998-99
Chairman, Urologic Discipline, American College of Osteopathic Surgeons, 1999 - 2000
Member, American College of Osteopathic Surgeons, Board of Governors, - 9/2000
Committee on Professional Guidance/Young Physicians POMA, 2003 - 2010
Committee on Tort Reform – POMA, 2003 - 2005
Committee on Organization Membership & Physician Placement, - POMA 2003, 2008, 2010 - present
Member, ACOS – Strategic Planning Committee, 2001 - present
Member, ACOS – College Governance Committee, 2004 - 2009
ACOS – ACA Coordinating Committee, 2004 - 2005
7
ACOS Chairman, ACA Coordinating Committee, 2005 - 2006
ACOS Chairman, Strategic Planning Committee, 2005 – 2009
Past President, American College of Osteopathic Surgeons, 2009 – present
National & State Committees – Continued:
President, American College of Osteopathic Surgeons, 2008 – 2009
President - Elect, American College of Osteopathic Surgeons, 2007 -2008
Member, Board of Governors, American College of Osteopathic Surgeons, 2000 – 2010
Chairman, Committee on Strategies for ABMS Recognition of AOBS Certification, ACOS, 2010 – present
Vice Chairman, Strategic Planning Committee, ACOS, 2010 – present
Member, Awards Committee ACOS, 1993 – present
Member, Committee on Surgery (Urology), POMA, 2010 – present
Chairman, American College of Osteopathic Surgeons, TRUST FUND, 2011- present
Member, Search Committee, ACOS EXECUTIVE DIRECTOR, 2011-2012
PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE - STANDING COMMITTEES:
College Admissions Committee, 1991 - 1995
College Discipline Committee, 1990 - 2002
Animal Care and Utilization Committee, 1989 - 1998
Chairman, Academic Planning and Budget, 1993 - 1996
Curriculum Committee, 2002 – present
Committee on Tenure, 2008 - 2010
PAPERS/ ABSTRACTS:
Carcinoid of the Appendix: A review of the literature and case report at Detroit Osteopathic Hospital, 1993.
The Use of Penile Prosthesis in Impotent Genitourinary Patients: The experience of the Osteopathic Medical Center of
Philadelphia. Presented at the Urologic Seminar, Macinac Island, M: 8-85 and Urologic Discipline, ACOS 10/85, POMA
Journal 5/87
Mucinous Adenocarcinoma of the Prostate: Review of the literature and case report. (6/86)
The Combined Use of Traditional Transurethral Electroresection of the Prostate with Neodynium-YAG Laser: (6/86).
Preliminary results presented at the Urologic Discipline, ACOS, Las Vegas 10/86, Published JAOA 10/88
8
PAPERS – Continued
Combined Transurethral Electroresection and Neodynium-YAG Laser Therapy for Obstructing Prostatism: Journal of
American Osteopathic Association, October 1988, pages 1219-1222.
Transrectal Resection of the Prostate Combined with Neodynium-YAG Laser Prostatectomy of Residual Tissue: ICALEO
1986 proceeding Volume 55 - Medicine and Surgery November 13, 1986.
Priapism Associated with Intranasal Cocaine Abuse: The Journal of Urology, Vol. 143, No. 3, March 1990, Pages 584585.
Early Detection of Stage A Prostate Carcinoma:
Combined use of Prostatic Specific Antigen in transrectal
ultrasonography. The Journal of the American Osteopathic Medical Association, Vol. 146, September, 1991, Pages 863897.
The Use of Autologous Blood in Radical Retropubic Prostatectomy: A comparison of predeposited autologous blood used
in conjunction with intraoperative auto-transfusion to the use of predeposited autologous blood alone. Journal of the
American Osteopathic Association. June 1994
Transurethral Microwave Hyperthermia in the Treatment of Chronic Non-Bacterial Prostatitis: Journal of the American
Osteopathic Association, Vol. 97, No. 2, pages 25-30, January 1997
Human Sexuality: Advances in Science and Options for Care. Supplemental Editor, JAOA 1 Vol 104 No 1 January 2004
Laparoscopic Repair of Iatrogenic Bladder Injury, Abstract Mid Atlantic Section of AVA, 2008
Tasquinimod and improved survival in men with metastatic castration –resistant prostate cancer: Results of long term
follow up of a randomized phase 2 placebo-controlled trial. Co-author ASCO Abstract #98057- 2012 ASCO Annual
Meeting (June1-5, 2012).
SEMINARS - SPEAKERS:
The Urologic Discipline of the American College of Osteopathic Surgeons at Mackinac Island,1985 “The Use of Penile
Prosthesis in Impotent GU Cancer Patients”
Urologic Seminar - 1985 at PCOM “Urologic Problems in the Aging Male”
American College of Osteopathic Surgeons Convention, San Diego, California -1985 Topic: “The Use of Penile Prosthesis
in Impotent GU Cancer Patients”
Urologic Seminar - 1986 at PCOM “Urinary Stress Incontinence”
American College of Osteopathic Surgeons Convention, Las Vegas - Nevada 1986 “The Combined Use of Traditional
Transurethral Electroresection of the Prostate with the Nd:YAG Laser”
Urologic Seminar - 1987 at PCOM “The Urodynamic Laboratory”
Urological Discipline Mid-Year Meeting, Saw Mill Creek Resort, Huron, Ohio - July 1988 – “Use of Streptokinase for Renal
Vein Thrombosis”
SEMINAR – SPEAKERS - Continued: Fifteenth Annual Urology Seminar, Philadelphia College of Osteopathic Medicine September 10,1988 – “Female Incontinence”
American College of Osteopathic Surgeons, New York, NY - October 1988: “Use of Transurethral Ultrasound in Diagnosis,
Staging and Follow-up of Neoplasms of the Urinary Bladder”
American College of Osteopathic Surgeons, New York, NY - October 1988: “Clinical Experience at OMCP Utilizing CO2
and Nd:YAG Laser Surgery in the Treatment of Penile Carcinoma”
9
Continent Urinary Diversion Workshop Seminar, Osteopathic Medical Center of Philadelphia, December 1 & 2, 1989
Suburban General Hospital - January 11, 1990 “Urinary Stress Incontinence”
Diabetes Education and Support Group at PCOM - March 18, 1991, Diabetes and Sexuality: “Impotence Affecting a Male
and Female”
American College of Osteopathic Surgeons Convention, Orlando, Florida - 9/29/92 “Overview of Bladder Carcinoma”
Urology Seminars at PCOM - 9/7/91, “Endourology - Update”
Family Practice Seminar of PCOM - 4/25/92, “BPH - Diagnosis and Therapy Options”
Acting Program Chairman, Urology Seminar at PCOM - 9/12/92, “Advanced Carcinoma of the Prostate - How and When
To Treat”
National Osteopathic Health Conference, Kansas City, Missouri - 4/17/93, “Etiology and Pathology of the UTI: Therapeutic
Options”
Family Practice Lecture - 11/18/94, “Update on UTI’s”
Urology Seminars at PCOM - 9/18/93, “Current Status Treatment of Ureteric Calculi”
Graduate Health System, Free Health Lecture Series at Graduate City Avenue Hospital - 10/93, “Impotence: Diagnosis &
Treatment”
Ob/Gyn Department Seminar at Graduate City Avenue Hospital - 3/21/94. “Urethral and Bladder Injuries: Diagnosis and
Treatment”
Suburban General Hospital - 3/28/95, “BPH - Diagnosis and Therapy”
Graduate Health System, Free Health Lecture Series at Graduate Parkview Hospital - 4/12/94, “Detecting and Treating
Prostate Cancer”
Urology Seminar of PCOM - 9/94, “Hematuria - Etiology Diagnosis Therapy”
Department of Surgery Graduate Health System / City Avenue Hospital - 9/95, “BPH - Diagnosis and Therapy Options”
Urology Seminar of PCOM - 9/30/95, “Stress Urinary Incontinence - Diagnosis and Management”
Urology Seminar of PCOM - 9/96, “Urology in the Geriatric Patient”
Urologic Conference PCOM - 5/97, “GU Fistulas”
Program Chairman, Urology Seminar - 9/27/97, “Urology in Women’s Health Care”
Guest Speaker - Radio Station WWDB 12/7/97- Discussion/Question & Answer Forum on Erectile Dysfunction
th
POMA – 90 Annual Clinical Assembly – 4/30/98 – “Urologic Office Procedures”
AOA/ACOFP 103rd Annual Convention and Scientific Seminar – October 8, 1998, New Orleans, Louisiana “Managing the
Older Male Patient With Erectile Dysfunction”
th
AOA/ACOFP 104 Annual Convention and Scientific Seminar – October 24-28, 1999, San Francisco, California “A Review
of Therapeutic Options in the Management of Erectile Dysfunction”
th
AOA/ACOFP 105 Annual Convention and Scientific Seminar October 29–November 2, 2000, Orlando, Florida “The
Epidemiology of Erectile Dysfunction”
th
27 Annual Urology Seminar - “Brachytherapy in the Treatment of Prostate Cancer” Philadelphia College of Osteopathic
Medicine 12/2/00
10
rd
POMA 93 Annual Clinical Assembly – May 3, 2001, Philadelphia, Pennsylvania “Management & Treatment of Recurrent
Urinary Tract Infections”
PCOM Family Practice Seminar – July 19, 2001, Hershey, Pennsylvania “The Epidemiology, Diagnosis and Current
Treatment of Erectile Dysfunction”
rd
POMA 95 Annual Clinical Assembly – May 2, 2003, Philadelphia, Pennsylvania “Management & Treatment of Recurrent
Urinary Tract Infections”
POMA District 10 – November 9, 2003, King of Prussia, Pennsylvania “Management of Erectile Dysfunction”
rd
POMA 96 Annual Clinical Assembly – April 28, 2004, Philadelphia, Pennsylvania “Men’s Health in the Millennium”
th
PA Osteopathic Family Physicians Society 29
Hyperplasia (BPH)”
Annual Convention - 8/15/04 “New Treatments in Benign Prostatic
PCOM Family Practice Seminar – July 7, 2005, Hershey, Pennsylvania “Men’s Health in the Millennium”
POMA Annual Clinical Assembly, May 2010, “Update on High Grade Prostatic Intraepithelial Neoplasia (PIN) in 2010”
ACOS, Annual Clinical Assembly, August 2010, “Update on High Grade PIN in 2010”
PCOM, CME Seminar, Program Chairman, “Advanced Technology and Hot Topics in Urology”, April 16, 2011
American Urologic Association, Late Breaking Oral Presentation – “Long Term Evaluation of Safety and Efficacy of
Avanafil in Males with Erectile Dysfunction” Washington, DC May 17, 2011
The ABC’s of Clinical Research in a Urologic Practice, Annual Clinical Assembly, ACOS September 17, 2011
SCIENTIFIC EXHIBITS AND POSTERS:
Use of Transurethral Ultrasound in Diagnosis, Staging and Follow-Up of Neoplasms of the Urinary Bladder:
American College of Osteopathic Surgeons, October 1988, New York, NY (FIRST PRIZE)
Clinical Experience at OMCP Utilizing CO2 and Nd:YAG Laser Surgery in the Treatment of Penile Carcinoma:
American College of Osteopathic Surge9ons, October 1988, New York, N (SECOND PRIZE)
Continent Urinary Diversion: American College of Osteopathic Surgeons, September 1989, St. Louis, Missouri (FIRST
PRIZE) Urologic Discipline
OMCP Clinical Experience with Uniflate Penile Prosthesis: American College of Osteopathic Surgeons, September
1989, St. Louis, Missouri (SECOND PRIZE) Urologic Discipline
Multidimensional Imaging of the Prostate Gland: American College of Osteopathic Surgeons, October 1990, Los
Angeles, California (SECOND PRIZE) Urologic Discipline
Laparoscopic Pelvic Node Dissection: American College of Osteopathic Surgeons, Orlando, Florida 1991
Pulse-Dye Laser Lithotripsy, Principles and Applications:
Illinois 10/92
American College of Osteopathic Surgeons, Chicago,
Physical Principles of ESWL: American College of Osteopathic Surgeons, Chicago, Illinois 1992
Adrenal Medullary Hyperplasia Presenting as a Pheochromocytoma: American College of Osteopathic Surgeons,
Chicago, Illinois 1992
11
Seventeen Years Experience with Bladder Pacemaker: American College of Osteopathic Surgeons, Chicago, Illinois
1992 (THIRD PLACE WINNER POSTER)
Use of Cell Saver and Autologous Transfusion in Radical Prostatectomy:
Surgeons, Chicago, Illinois 1992
Pulse-Dye Laser Lithotripsy (Video):
PLACE WINNER) Urologic Discipline.
American College of Osteopathic
American College of Osteopathic Surgeons, Chicago, Illinois 1992. (FIRST
Leiomyosarcoma of the Scrotum, An Uncommon Paratesticular Tumor: American College of Osteopathic Surgeons,
Washington, DC 1994 Poster
Metastatic Seretoli Cell Carcinoma of the Testes: American College of Osteopathic Surgeons, Washington, DC 1994
Poster
The Use of Color Flow Doppler Ultrasound in the Management of Acute Testicular Torsion: American College of
Osteopathic Surgeons, Washington, DC 1994 Poster
Transurethral Microwave Hyperthermia for the Treatment of Chronic Non-Bacterial Prostatitis: American College of
Osteopathic Surgeons, New Orleans, Louisiana 9/95 (FIRST PLACE WINNER)
Family Practice Perspective on the Treatment of Men with Lower Urinary Tract Sytmptoms: American College of
Osteopathic Surgeons, Chicago, Illinois September 2003 - Poster
Factors Affecting the Relationship Between Gleason Score at Biopsy with Gleason Score at Prostatectomy:
American College of Osteopathic Surgeons, Chicago, Illinois September 2003 - Poster
Malleable Penile Prosthesis Implantation in Men with Spina Bifida
American College of Osteopathic Surgeons, Orlando, Florida – October 2005
Pathological Characteristics of Positive Repeat Prostate Biopsies After Initial Negative or Suspicious Biopsy
American College of Osteopathic Surgeons, Orlando, Florida – October 2005 (Second Place Winner)
Long Term Evaluation of Safety and Efficacy of Avanafil in Males with Erectile Dysfunction, AUA Washington DC
May 17, 2010
Patients Improve When Switching from Finasteride to Dutasteride, AUA,Washington, DC May 2011, ACOS Atlanta,
GA September 2011.
CLINICAL RESEARCH EXPERIENCE:
Principal Investigator: 1987- present
Provide medical oversight for study subjects
Responsible for all study related issues
Benign Prostatic Hypertrophy
Prospective, Observational Registry and Patient Survey of the Management of Men With Symptomatic Benign Prostatic
Hyperplasia (BPH): BPH Registry and Patient Survey Sanofi-Synthelabo
AEZS-102-041 Cetrorelix pamoate (AEZS-102) in Patients with Symptomatic BPH: An Open-Labeled Safety and Efficacy
Assessment Study. 2008
SPI-153-08-1: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix,
in Patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hypertrophy (BPH)
12
SI08005 A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men
With Benign Prostatic Hyperplasia 2009
MCS-2-US-a
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study To Establish The Dosage, Efficacy, And
Safety Of L-O-M® MCS In Treating Lower Urinary Tract Symptoms Suggestive Of Benign Prostatic Hyperplasia In
Treatment-Naïve Male Subjects 2010
MCS-2-US-c
An Open-Label, Six-Month Extension of Protocol MCS-2-US-a to Further Evaluate the Efficacy and Safety of L-O-M® MCS
for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment-Naïve Male
Subjects 2010
I1A-MC-BPAE: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower
Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH) 2010
PRX302-2-06 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Safety and Efficacy Study of
a Single Transrectal Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms Secondary to Benign Prostatic
Hyperplasia 2011
H6D-MC-LVIR: A Randomized, Double Blind Placebo-Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8
Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Benign Prostatic
Hyperplasia.2012
NX02-0017 Phase 3 Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Clinical Evaluation Of Nx1207 For The Treatment Of BPH 2012
Bladder Cancer
V560-02-08C06-1: Validation of the AutoFISH™ UroVysion™ Bladder Cancer Kit on the BioGenex Xmatrx™ Automated
Slide Staining System Specimen Collection and Specimen Testing Protocol.
SPI-611: A Multicenter, Randomized Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin
as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for
Noninvasive Bladder Cancer.2007
EN3329-301: A Phase 3b, Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of
Maintenance Therapy With Valrubicin Versus No Maintenance, In Subjects Treated With Valrubicin Induction For
Carcinoma In Situ (Cis) Of The Bladder
13
EN3348-302 - Randomized, double-blind, multi-center studycomparing MCC to BCG as first line immunotherapy in
patients with non-muscle invasive(superficial) bladder cancer at high risk of recurrence or progression 2009
CR-PF027 ClinPath Advisors Urine Specimen Collection from Subjects with Bladder Cancer. 2010
EN3348-303: A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and
Safety of EN3348 (MCC) as Compared with Mitomycin C in the Intravesical Treatment of Subjects with BCG Recurrent or
Refractory Non-Muscle Invasive Bladder Cancer 2011
EN3329-401 A Retrospective Analysis To Evaluate The Effectiveness, Safety And Tolerability Of Intravesical Valrubicin
For The Treatment Of Bladder Carcinoma In Situ In Clinical Practice 2011
EN3329-402 A Prospective Registry To Assess The Effectiveness And Local Tolerability Of Intravesical Valrubicin In
Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC) 2011
SPI-1011: A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the
Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients with Low-Intermediate Risk
Non-Muscle Invasive Bladder Cancer (NMIBC) 2012
Erectile Dysfunction
A1481179 A Multicenter, Open Label, Flexible Dose Study To Investigate The Use Patterns of Viagra® (sildenafil citrate)
And The Ability Of Investigators To Further Optimize Subject Satisfaction With Viagra® Through Customized Instruction.
Pfizer Closed 6/04
100477 Real Life Safety and Efficacy – A Post Marketing Surveillance Study of Levitra Bayer
NexMed -2000-004 Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 3 Trial of the Efficacy and
Safety of Alprox TD in Male Patients with Erectile Dysfunction. - Closed 12/2002
NexMed 2000-006 Open-Label, Parallel Design, Long-term Phase III Trial of the Safety and Efficacy of Alprox-TD in Male
Patients with Erectile Dysfunction. Discontinued 11/2002 – Sponsor Decision
PT-141-2004-16A A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study to Evaluate the Efficacy
and Safety of Intranasally Administered PT 141 in Subjects with Erectile Dysfunction
PT-141-2005-17A A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study to Evaluate the Efficacy
and Safety of Intranasally Administered PT 141 in Subjects with Erectile Dysfunction and Diabetes Mellitus
The ZEN Study: The Medtronic Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in
Males with Sub-optimal Response to PDE5 Inhibitors IP110 Rev. C 2009
14
TA 301 A Randomized, Double-Blind, Placebo-Controlled Evaluation of The Safety And Efficacy Of Avanafil (Ta-1790) In
Subjects With Generalized Erectile Dysfunction 2009
PR-01209 A Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and
Efficacy of WC3043 Tablets in Male Subjects with Erectile Dysfunction. 2009
H6D-US-LVIP: Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment
of Return to Normal Erectile Function 2010
TA-302 A Randomized, Double-Blind, Placebo-Controlled Evaluation Of The Safety And Efficacy Of Avanafil (Ta-1790) In
The Treatment Of Erectile Dysfunction In Diabetic Men 2010
TA-303 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of
Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy 2010
TA-314 An Open-Label, Long-Term Evaluation of the Safety and Efficacy of Avanafil in Men With Erectile Dysfunction
2010
PR-01409 An Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of WC3043 Tablets in Male
Subjects With Erectile Dysfunction 2010
Hypogonadism
IP157-001 A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of
Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men. 2007
S1762101 A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of
AndroGel®, as an Adjunct to Oral Hypoglycemic Therapy, in the Treatment of Hypogonadal and Low Testosterone Men
with Type 2 Diabetes.
CLAR-09007 Phase III, Active Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in
Hypogonadal Men. Clarus 2011
Incontinence
F1J-US-SBCD Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-morbidities with
Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Lilly & Boehringer Ingelheim
C-98-008-00 Open-Label Study to Evaluate Patient Acceptance and Safety of OROS Oxybutynin Chloride in Urge Urinary
Incontinence. Alza Corporation Clinical - Completed 12/99
15
PNEU-01-004 A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify
Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence 2008
20070060 A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment
with Topically Administered Oxybutynin Gel in Patients with Urinary Frequency, and Urge and Mixed Urinary Incontinence
with a Predominance of Urge Incontinence Episodes with an Open-Label Extension. 2009
905-UC-050: A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-center Study to Assess Efficacy
and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted
Radical Prostatectomy 2011
Interstital Cystitis
A4091035 – 1070 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The
Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/
Painful Bladder Syndrome (Ic/Pbs).
Kidney Stones
SIL1001 A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage 2011
Overactive Bladder Studies
332-004 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Parallel Group Study – Dose-Range Study to
Evaluate Unstable Bladder Condition. Sepracore– Completed 1/2000
OXY0402 Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin TDS Watson
Laboratories Inc
583E-URO-0084-023 Phase III, Open-Label, Single-Arm Trial in Adult Patients with Overactive Bladder and Symptoms of
Urinary Frequency, Urgency and/or Urge Incontinence. Pharmacia & Upjohn Co. Closed 7/2001
332-146 Double-Blind, Placebo and Active Controlled Study of Sustained Release (S)-Oxybutynin in Subjects with
Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence. Sepracor– Closed 9/20/02
331-151 Open-label Extension Study of Sustained Release (S)-Oxybutynin in Subjects with Symptoms of Overactive
Bladder. Sepracor – Closed 9/2002
583E-URO-0084-037 Randomized Study to Evaluate the Effect of Tolterodine Prolonged Release on Nocturia in Patients
Suffering from Overactive Bladder (OAB) in USA Pharmacia / Pfizer
DETAOD-0084-047.Assessment of the Efficacy of Tolterodine ER versus Placebo for the Symptom of Urgency and the
Improvement in Bladder Condition. Pharmacia
16
A6121120 A Randomized, Double Blind , Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and
Tolterodine ER Plus Tamsulosin) Study to evaluate The Clinical Efficacy and Safety of Tolterodine ER 4 mg in Men Who
Have Frequency and Urgency, With or Without Urinary Urge Incontinence, With or Without Bladder Outlet Obstruction Pfizer
YPA 905-UC-007 Open-Label Study of the Efficacy and Safety of 5 and 10 mg Vesicare (Solifenacin Succinate) In Patients
with Overactive Bladder Symptoms Yamanouchi Pharma America
IP631-022 A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study Of Safety And Efficacy Of Trospium
Chloride 60 Mg Modified Release Capsules Versus Placebo, Once Daily, For 12 Weeks Followed By A 9-Month, OpenLabel Treatment Phase In Patients With Overactive Bladder Protocol.
905-UC-008 A Randomized, Double –Blind, Placebo controlled, Parallel Group, Mulitcenter Safety and Efficacy, Phase 4
Study of VESICare (Solifenacin Succinate) or Placebo in combination with Tamsulosin HCL for the Treatment of Residual
OAB symptoms of Urgency and Frequency in Men.
191622-077-03 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Response Study Of
The Safety And Efficacy Of A Single Treatment Of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex In
Patients With Idiopathic Overactive Bladder With Urinary Urge Incontinence 2007
905-UC-010 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-Center Study Of Vesicare®
(Solifenacin Succinate) In Overactive Bladder (OAB) Subjects To Evaluate Symptom Bother And Health Related Quality Of
Life VIBRANT: Vesicare® Investigation Of Bother And Quality Of Life In Subjects With OAB 2007
Protocol MCP101-1001: The Effect of Intravesical Doses of Resiniferatoxin (RTX) in Subjects with Overactive Bladder
who are Refractory to Antimuscarinic Therapy: A Phase I/II Double-blind, Placebo-controlled, Dose-escalation Study. 2008
178-CL-074 A Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of
Overactive Bladder Astellas
178-CL-049 A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the
Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive
Bladder
FE992026 CS31: A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast- Dissolving
("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
FE 992026 CS40: A Multi-Centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the
Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females
17
FE 992026 CS41: A Multi-Centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label
Extension to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablets for the Treatment of
Nocturia in Adult Males
A0221009 – 1061 A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of
Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of
Alpha Blocker For Lower Urinary Tract Symptoms
SPC-SER120-DB2-200902 A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the
Efficacy and Safety of SER120 Nasal Spray Formulation in Patients with Nocturia (Non-PK Study) 2009
SPC-SER120-OL1-200903 "A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray
Formulations in Patients with Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902"
2010
A0221048 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy
And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including
Nocturnal Urinary Urgency
A0221094 A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8
Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Er
GMA-SXR-09-004 A Multi-Center, Double-Blind, Placebo-Controlled Trial Of Sanctura Xr 60 Mg Daily In Female Oab
Patients On Multiple Concomitant Medications Refractory To Er Tolterodine 4mg Daily 2010
NKB105022 A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Forced Titration, Proof of
Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of 60 mg and 120 mg
of GW679769 administered once daily vs Placebo in Women with Overactive Bladder
Prostate Cancer Studies
Combined Use of Traditional Transurethral Electroresection of the Prostate with Nd:YAG Laser, Phase II (Human) –
Completed 1987
The Determination of the Specificity and Sensitivity of Prostatic Specific Antigen and Transrectal Ultrasound in Detecting
Stage A Prostatic Carcinoma Prior to Prostatectomy. – Completed 1988
Efficacy of Ciprofloxacin in Patients Undergoing Transrectal Needle Biopsy of the Prostate. Randomness or double blind
study with placebo. – Completed 1987
18
CyPAT PCA 301 A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the
Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical
Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients 2002
CZOL446E US24 - An Open-label Trial on the Effect of I.V. Zometa 4 mg on Bone Mineral Density in Hormone Sensitive
Prostate Cancer Patients with Bone Metastasis. 2003
ARI40006 REDUCE A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of
Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate
Cancer. GlaxoSmithKline 2003
Phase III, Open-Label, Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal
Implant in Patients with Advance Prostate Cancer. Hydro Med Sciences Protocol 301 Closed 7/04
G300203. A Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate
for the Prevention of Bone Fractures in men with Prostate Cancer on Androgen Deprivation Therapy. 2004
GTX-006-211 Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the
Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20 mg., 40 mg & 60 mg Daily of GTx-006 in Men
with High Grade Prostate Intraepithelial Neoplasia (PIN). 2004
ARI103094-Follow-Up Study for REDUCE Study Subjects
G-0029 A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in
Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve Cell Genesys 2006
XRP6976J/3503 A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate
Cancer Subjects With a Rising PSA
AVO105948: A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in
Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing
Expectant Management 2006
DR-PCA-201: A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Dose-Ranging Clinical Trial To
Study The Efficacy And Safety of 5, 15 or 25mg/day CyPat™ (Cyproterone Acetate) for the Treatment of Hot Flashes
Following Surgical or Medical Castration of Prostate Cancer Patients. 2006
07TASQ08: Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in
Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer 2007 – 2010
19
AVO108943:A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus
Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with
Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a
Two-Year Extension Phase 2007
030-00 A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone MetastasisFree Survival in Men with Hormone-Refreactory Prostate Cancer. 2008
PE0814 Performance Evaluation of the AMS CONTINUUMTM Device in Facilitating Vesico-urethral Anastomosis
Following a Radical Prostatectomy 2009
11TASQ11 Retrospective follow-up for Overall Survival in the clinical study: Phase II Randomized Double Blind Placebo Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant
Prostate Cancer
FSI-003: A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate
cancer with HIFU (STAR Trial) 2009
FE 200486 CS35: An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and
Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring
Androgen Deprivation Therapy 2009
10TASQ10 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic
Castrate-Resistant Prostate Cancer 2011
GP/C/05/PRO Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate
Cancer 2011
9785-CL-0222: A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs Bicalutamide
in Castrate Men with Metastatic Prostate Cancer 2011
P10-3: PROCEED A registry of sipuleucel-t therapy in men with advanced prostate cancer 2011
G200705: Phase II, open label, dose finding study of the effect of GTx-758 on total and free testosterone levels in men
with prostate cancer compared to a luteinizing hormone releasing hormone agonist 2011
G200707: Open label study of the effect of GTx-758 on serum PSA and free testosterone levels in men with castration
resistant prostate cancer and maintained on androgen deprivation therapy 2011
G200710: Phase II, open label, loading and maintenance dose finding study of GTx-758 in men with prostate cancer 2011
20
L-PC07-169: A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6Month Leuprolide Formulations in Subjects with Prostatic Adenocarcinoma
20080560:A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with
Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy 2012
BNIT-PRV-301: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With
Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer 2012
Prostatitis
CAPSS-101 Multicenter, Double-Blind Study to Compare Safety & Efficacy of Levofloxacin to Ciprofloxacin in the
Treatment of Chronic Prostatitis. Ortho-McNeil Pharmaceutical – Protocol– Closed 3/2001
CAPSS-263 Double-Blind Randomized, Placebo-Controlled Trial of Elmiron (Pentosan Polysulfate Sodium) for the
Treatment of Chronic Non-Bacterial Prostatitis Ortho McNeil - 2006
LEVOINI3002 A Multicenter, Double-Blind Phase 3B Study To Compare The Safety And Efficacy Of Levofloxacin 750mg
For 2 Weeks And Levofloxacin 500mg For 4 Weeks In The Treatment Of Chronic Prostatitis. 2007
Urinary Tract Infection
100534 Phase IV open label, non-comparative multicenter study – The Express Trial – Efficacy and safety of once Daily
Cipro XR in the treatment of UTI, as well as the impact of disease directed educational material on patients’ knowledge
and treatment of their urinary tract infection.
CAPSS-349 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficiacy Of Leveofloxacin
750mg Once Daily For Five Days Versus Ciproflaxacin HCL 500mg Twice Daily For Ten Days In The Treatment Of
Complicated Urinary Tract Infection Of Acute Uncomplicated Pyelonephritis. 2004
Miscellaneous Studies
0302-0 Open-label, Large Simple Usual Care Study of the Effect of Adding Rofecoxib 50 mh to a Regimen of Selected
Opoid Analgesic PRN in Patients Undergoing Selected Outpatient Surgical Procedures. Merck -VIOXX Protocol
AUX-CC-802: A Phase 3, Open-Label Study of the Safety and Effectiveness of AA4500 Administered Twice Per
Treatment Cycle For Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease 2011
21
A-10025, Evaluating the Psychometric Properties and Content Validity of the Peyronie's Disease Questionnaire (PDQ)
Auxilium 2011
TCBIO-001-0710 Observational Study Title: The Caris Biorepository Research 2011
OTB109059 A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability,
Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, PlaceboControlled, Parallel Group Study in Men with Premature Ejaculation